Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712

Genomic analyses identify molecular subtypes of pancreatic cancer

Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874

Organoid models of human and mouse ductal pancreatic cancer

Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150

Integrated genomic characterization of pancreatic ductal adenocarcinoma

Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019

Pancreatic cancer

Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06063-y · Cited by 1,432

Pancreatic cancer: Advances and challenges

Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321

Estimated Projection of US Cancer Incidence and Death to 2040

Rahib, L., Wehner, M. R., Matrisian, L. M., & Nead, K. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.4708 · Cited by 1,339

Optimizing the outcomes of pancreatic cancer surgery

Strobel, O., Neoptolemos, J., Jäger, D., & Büchler, M. W. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0112-1 · Cited by 943

Molecular subtypes of pancreatic cancer

Collisson, E. A., Bailey, P., Chang, D. K., & Biankin, A. V. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0109-y · Cited by 892

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875

Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma

Groot, V. P., Rezaee, N., Wu, W., Cameron, J. L., Fishman, E. K., Hruban, R. H., Weiss, M. J., Zheng, L., Wolfgang, C. L., & He, J. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002234 · Cited by 757

Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial

Versteijne, E., van Dam, J. L., Suker, M., Janssen, Q. P., Groothuis, K., Akkermans-Vogelaar, J. M., Besselink, M. G., Bonsing, B. A., Buijsen, J., Busch, O. R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02233 · Cited by 786

MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells

Sancho, P., Burgos-Ramos, E., Tavera, A., Bou Kheir, T., Jagust, P., Schoenhals, M., Barneda, D., Sellers, K., Campos-Olivas, R., Graña, O., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.08.015 · Cited by 722

Challenges and Opportunities for Pancreatic Cancer Immunotherapy

Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674

Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features

Puleo, F., Nicolle, R., Blum, Y., Cros, J., Marisa, L., Demetter, P., Quertinmont, E., Svrcek, M., Elarouci, N., Iovanna, J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.033 · Cited by 563

Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer

Hart, P. A., Bellin, M. D., Andersen, D. K., Bradley, D., Cruz-Monserrate, Z., Forsmark, C. E., Goodarzi, M. O., Habtezion, A., Korc, M., Kudva, Y. C., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30106-6 · Cited by 551

Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer

Huang, H., Wang, Z., Zhang, Y., Pradhan, R. N., Ganguly, D., Chandra, R., Murimwa, G., Wright, S., Gu, X., Maddipati, R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.011 · Cited by 542

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer

Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02627 · Cited by 522

Diabetes, pancreatogenic diabetes, and pancreatic cancer

Andersen, D. K., Korc, M., Petersen, G. M., Eibl, G., Li, D., Rickels, M. R., Chari, S. T., & Abbruzzese, J. L. (2017) · Diabetes · doi:10.2337/db16-1477 · Cited by 516

Early detection of pancreatic cancer

Pereira, S. P., Oldfield, L., Ney, A., Hart, P. A., Keane, M. G., Pandol, S. J., Li, D., Greenhalf, W., Jeon, C. Y., Koay, E. J., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30416-9 · Cited by 482

Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma

Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Padrón, L. J., Maurer, D. M., O’Hara, M. H., O’Reilly, E. M., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01829-9 · Cited by 384

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine

Aguirre, A. J., Nowak, J. A., Camarda, N. D., Moffitt, R. A., Ghazani, A. A., Hazar-Rethinam, M., Raghavan, S., Kim, J., Brais, L. K., Ragon, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0275 · Cited by 367

Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data

Connor, A. A., & Gallinger, S. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00418-1 · Cited by 369

A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories

Placido, D., Yuan, B., Hjaltelin, J. X., Zheng, C., Haue, A. D., Chmura, P. J., Yuan, C., Kim, J., Umeton, R., Antell, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02332-5 · Cited by 349

Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers

Singhi, A. D., George, B., Greenbowe, J. R., Chung, J., Suh, J., Maitra, A., Klempner, S. J., Hendifar, A., Milind, J. M., Golan, T., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.037 · Cited by 348

Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis

Wolf, E., Rich, N. E., Marrero, J. A., Parikh, N. D., & Singal, A. G. (2021) · Hepatology · doi:10.1002/hep.31309 · Cited by 333

A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression

Auciello, F. R., Bulusu, V., Oon, C., Tait-Mulder, J., Berry, M., Bhattacharyya, S., Tumanov, S., Allen-Petersen, B. L., Link, J., Kendsersky, N. D., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1212 · Cited by 332

BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study

Zhen, D. B., Rabe, K. G., Gallinger, S., Syngal, S., Schwartz, A. G., Goggins, M. G., Hruban, R. H., Cote, M. L., McWilliams, R. R., Roberts, N. J., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.153 · Cited by 295

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Melisi, D., Garcia-Carbonero, R., Macarulla, T., Pezet, D., Deplanque, G., Fuchs, M., Trojan, J., Oettle, H., Kozloff, M., Cleverly, A., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0246-z · Cited by 294

Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis

Santana-Codina, N., Roeth, A. A., Zhang, Y., Yang, A., Mashadova, O., Asara, J. M., Wang, X., Bronson, R. T., Lyssiotis, C. A., Ying, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07472-8 · Cited by 252

Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers

Kim, J., Bamlet, W. R., Oberg, A. L., Chaffee, K. G., Donahue, G., Cao, X.-J., Chari, S., Garcia, B. A., Petersen, G. M., & Zaret, K. S. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah5583 · Cited by 269

Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative

Pishvaian, M. J., Bender, R. J., Halverson, D., Rahib, L., Hendifar, A. E., Mikhail, S., Chung, V., Picozzi, V. J., Sohal, D., Blais, E. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0531 · Cited by 245

Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors

Xiao, Z., Todd, L., Huang, L., Noguera-Ortega, E., Lu, Z., Huang, L., Kopp, M., Li, Y., Pattada, N., Zhong, W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40850-5 · Cited by 272

An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis

Atiq, O., Tiro, J., Yopp, A. C., Muffler, A., Marrero, J. A., Parikh, N. D., Murphy, C., McCallister, K., & Singal, A. G. (2017) · Hepatology · doi:10.1002/hep.28895 · Cited by 266

Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer

Elgogary, A., Xu, Q., Poore, B., Alt, J., Zimmermann, S. C., Zhao, L., Fu, J., Chen, B., Xia, S., Liu, Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611406113 · Cited by 234

Molecular Pathogenesis of Pancreatic Cancer

Grant, T. J., Hua, K., & Singh, A. (2016) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2016.09.008 · Cited by 237

CSF1R(+) macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype

Candido, J. B., Morton, J. P., Bailey, P., Campbell, A. D., Karim, S. A., Jamieson, T., Lapienyte, L., Gopinathan, A., Clark, W., McGhee, E. J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.131 · Cited by 224

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms

Lowery, M. A., Wong, W., Jordan, E. J., Lee, J. W., Kemel, Y., Vijai, J., Mandelker, D., Zehir, A., Capanu, M., Salo-Mullen, E., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy024 · Cited by 224

Deep learning to distinguish pancreatic cancer tissue from non-cancerous pancreatic tissue: a retrospective study with cross-racial external validation

Liu, K.-L., Wu, T., Chen, P.-T., Tsai, Y. M., Roth, H., Wu, M.-S., Liao, W.-C., & Wang, W. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30078-9 · Cited by 222

Fasting blood glucose levels provide estimate of duration and progression of pancreatic cancer before diagnosis

Sharma, A., Smyrk, T. C., Levy, M. J., Topazian, M. A., & Chari, S. T. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.025 · Cited by 204

Identification of a three-biomarker panel in urine for early detection of pancreatic adenocarcinoma

Radon, T. P., Massat, N. J., Jones, R., Alrawashdeh, W., Dumartin, L., Ennis, D., Duffy, S. W., Kocher, H. M., Pereira, S. P., Guarner (posthumous), L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2467 · Cited by 203

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

Noel, M., O’Reilly, E. M., Wolpin, B. M., Ryan, D. P., Bullock, A. J., Britten, C. D., Linehan, D. C., Belt, B. A., Gamelin, E. C., Ganguly, B., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00830-3 · Cited by 199

Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma

Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu, R., Whyte, D., Hedley, A., Laing, S., Kruspig, B., Upstill-Goddard, R., Shaw, R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0620 · Cited by 182

Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer

Masoud, R., Reyes-Castellanos, G., Lac, S., Garcia, J., Dou, S., Shintu, L., Abdel Hadi, N., Gicquel, T., El Kaoutari, A., Diémé, B., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100143 · Cited by 175

Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance

Dalin, S., Sullivan, M. R., Lau, A. N., Grauman-Boss, B., Mueller, H. S., Kreidl, E., Fenoglio, S., Luengo, A., Lees, J. A., Vander Heiden, M. G., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0960 · Cited by 156

Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma

Chung, K. M., Singh, J., Lawres, L., Dorans, K. J., Garcia, C., Burkhardt, D. B., Robbins, R., Bhutkar, A., Cardone, R., Zhao, X., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.062 · Cited by 150

Therapeutic targeting of the Warburg effect in pancreatic cancer relies on an absence of p53 function

Rajeshkumar, N. V., Dutta, P., Yabuuchi, S., de Wilde, R. F., Martinez, G. V., Le, A., Kamphorst, J. J., Rabinowitz, J. D., Jain, S. K., Hidalgo, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0108 · Cited by 158

Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review

Kenner, B., Chari, S. T., Kelsen, D., Klimstra, D. S., Pandol, S. J., Rosenthal, M., Rustgi, A. K., Taylor, J. A., Yala, A., Abul-Husn, N., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001762 · Cited by 158

Familial pancreatic cancer

Petersen, G. M. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.09.002 · Cited by 157

Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer

Mellby, L. D., Nyberg, A. P., Johansen, J. S., Wingren, C., Nordestgaard, B. G., Bojesen, S. E., Mitchell, B. L., Sheppard, B. C., Sears, R. C., & Borrebaeck, C. A. K. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6658 · Cited by 159

Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history

Chaffee, K. G., Oberg, A. L., McWilliams, R. R., Majithia, N., Allen, B. A., Kidd, J., Singh, N., Hartman, A.-R., Wenstrup, R. J., & Petersen, G. M. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.85 · Cited by 144

Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications

Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149

Current and Emerging Therapies in Metastatic Pancreatic Cancer

Manji, G. A., Olive, K. P., Saenger, Y. M., & Oberstein, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2319 · Cited by 145

The PDAC extracellular matrix: a review of the ECM protein composition, tumor cell interaction, and therapeutic strategies

Perez, V. M., Kearney, J. F., & Yeh, J. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751311 · Cited by 143

Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients

Hu, C., Hart, S. N., Bamlet, W. R., Moore, R. M., Nandakumar, K., Eckloff, B. W., Lee, Y. K., Petersen, G. M., McWilliams, R. R., & Couch, F. J. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0455 · Cited by 137

Early detection of pancreatic cancer using DNA-based molecular approaches

Singhi, A. D., & Wood, L. D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00470-0 · Cited by 127

Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms

Permuth, J. B., Collaborative, T. F. P., Choi, J., Balarunathan, Y., Kim, J., Chen, D.-T., Chen, L., Orcutt, S., Doepker, M. P., Gage, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11768 · Cited by 127

Fully end-to-end deep-learning-based diagnosis of pancreatic tumors

Si, K., Xue, Y., Yu, X., Zhu, X., Li, Q., Gong, W., Liang, T., & Duan, S. (2021) · Theranostics · doi:10.7150/thno.52508 · Cited by 120

Differential contribution of pancreatic fibroblast subsets to the pancreatic cancer stroma

Garcia, P. E., Adoumie, M., Kim, E. C., Zhang, Y., Scales, M. K., El-Tawil, Y. S., Shaikh, A. Z., Wen, H.-J., Bednar, F., Allen, B. L., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.05.004 · Cited by 110

Cell of origin influences pancreatic cancer subtype

Flowers, B. M., Xu, H., Mulligan, A. S., Hanson, K. J., Seoane, J. A., Vogel, H., Curtis, C., Wood, L. D., & Attardi, L. D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0633 · Cited by 118

Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review

de Geus, S. W. L., Eskander, M. F., Kasumova, G. G., Ng, S. C., Kent, T. S., Mancias, J. D., Callery, M. P., Mahadevan, A., & Tseng, J. F. (2017) · Cancer · doi:10.1002/cncr.30856 · Cited by 118

Epithelial and stromal co-evolution and complicity in pancreatic cancer

Hingorani, S. R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00530-w · Cited by 108

Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and C-RAF

Blasco, M. T., Navas, C., Martín-Serrano, G., Graña-Castro, O., Lechuga, C. G., Martín-Díaz, L., Djurec, M., Li, J., Morales-Cacho, L., Esteban-Burgos, L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.002 · Cited by 115

Antidiabetic adiponectin receptor agonist AdipoRon suppresses tumour growth of pancreatic cancer by inducing RIPK1/ERK-dependent necroptosis

Akimoto, M., Maruyama, R., Kawabata, Y., Tajima, Y., & Takenaga, K. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0851-z · Cited by 104

Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches

Truong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102

Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance

Abe, T., Blackford, A. L., Tamura, K., Ford, M., McCormick, P., Chuidian, M., Almario, J. A., Borges, M., Lennon, A. M., Shin, E. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01512 · Cited by 102

SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma

Dardare, J., Witz, A., Merlin, J.-L., Gilson, P., & Harlé, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103534 · Cited by 101

Extracellular matrix requirements for gastrointestinal organoid cultures

Rezakhani, S., Gjorevski, N., & Lutolf, M. P. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121020 · Cited by 100

Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer

Tamura, K., Yu, J., Hata, T., Suenaga, M., Shindo, K., Abe, T., MacGregor-Das, A., Borges, M., Wolfgang, C. L., Weiss, M. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720588115 · Cited by 95

Silibinin-Mediated Metabolic Reprogramming Attenuates Pancreatic Cancer-Induced Cachexia and Tumor Growth

Shukla, S. K., Dasgupta, A., Mehla, K., Gunda, V., Vernucci, E., Souchek, J., Goode, G., King, R., Mishra, A., Rai, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5843 · Cited by 96

Genetics of familial and sporadic pancreatic cancer

Wood, L. D., Yurgelun, M. B., & Goggins, M. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.039 · Cited by 91

Focal Parenchymal Atrophy of Pancreas: An Important Sign of Underlying High-Grade Pancreatic Intraepithelial Neoplasia Without Invasive Carcinoma, i.e., Carcinoma in Situ

Nakahodo, J., Kikuyama, M., Nojiri, S., Chiba, K., Yoshimoto, K., Kamisawa, T., Horiguchi, S.-I., & Honda, G. (2020) · Pancreatology · doi:10.1016/j.pan.2020.09.020 · Cited by 87

Targeting TGFβR2‐mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer

Huang, H., Zhang, Y., Gallegos, V., Sorrelle, N., Zaid, M. M., Toombs, J., Du, W., Wright, S., Hagopian, M., Wang, Z., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910515 · Cited by 87

Factors associated with missed and misinterpreted cases of pancreatic ductal adenocarcinoma

Kang, J. D., Clarke, S. E., & Costa, A. F. (2021) · European Radiology · doi:10.1007/s00330-020-07307-5 · Cited by 84

Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance

Suenaga, M., Yu, J., Shindo, K., Tamura, K., Almario, J. A., Zaykoski, C., Witmer, P. D., Fesharakizadeh, S., Borges, M., Lennon, A.-M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2463 · Cited by 81

Patient-derived xenograft models of pancreatic cancer: overview and comparison with other types of models

Garcia, P. L., Miller, A. L., & Yoon, K. J. (2020) · Cancers · doi:10.3390/cancers12051327 · Cited by 77

Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review

Rahib, L., Fleshman, J. M., Matrisian, L. M., & Berlin, J. D. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0585 · Cited by 73

YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma

Tu, B., Yao, J., Ferri-Borgogno, S., Zhao, J., Chen, S., Wang, Q., Yan, L., Zhou, X., Zhu, C., Bang, S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130811 · Cited by 75

Noninvasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in Urine

Arasaradnam, R. P., Wicaksono, A., O’Brien, H., Kocher, H. M., Covington, J. A., & Crnogorac-Jurcevic, T. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.09.054 · Cited by 73

Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy

Ramot, Y., Rotkopf, S., Gabai, R. M., Zorde Khvalevsky, E., Muravnik, S., Marzoli, G. A., Domb, A. J., Shemi, A., & Nyska, A. (2016) · Toxicologic Pathology · doi:10.1177/0192623316645860 · Cited by 64

Endometrial cancer trends by race and histology in the USA: projecting the number of new cases from 2015 to 2040.

Gaber, C., Meza, R., Ruterbusch, J. J., & Cote, M. L. (2017) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-016-0292-2 · Cited by 66

Loss of Rnf43 accelerates kras-mediated neoplasia and remodels the tumor immune microenvironment in pancreatic adenocarcinoma

Hosein, A. N., Dangol, G., Okumura, T., Roszik, J., Rajapakshe, K., Siemann, M., Zaid, M., Ghosh, B., Monberg, M., Guerrero, P. A., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.12.273 · Cited by 61

Early detection initiative: a randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma

Chari, S. T., Maitra, A., Matrisian, L. M., Shrader, E. E., Wu, B. U., Kambadakone, A., Zhao, Y.-Q., Kenner, B., Rinaudo, J. A. S., Srivastava, S., et al. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106659 · Cited by 62

Adiponectin receptor agonists inhibit leptin induced pSTAT3 and in vivo pancreatic tumor growth

Messaggio, F., Mendonsa, A. M., Castellanos, J., Nagathihalli, N. S., Gorden, L., Merchant, N. B., & VanSaun, M. N. (2017) · Oncotarget · doi:10.18632/oncotarget.19905 · Cited by 60

Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice

Hao, F., Xu, Q., Wang, J., Yu, S., Chang, H.-H., Sinnett-Smith, J., Eibl, G., & Rozengurt, E. (2019) · PLOS ONE · doi:10.1371/journal.pone.0216603 · Cited by 55

Pancreatic cancer in Lynch syndrome patients

Bujanda, L., & Herreros-Villanueva, M. (2017) · Journal of Cancer · doi:10.7150/jca.20750 · Cited by 57

Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer: From Concept to Reality

Serrano, J., Andersen, D. K., Forsmark, C. E., Pandol, S. J., Feng, Z., Srivastava, S., & Rinaudo, J. A. S. (2018) · Pancreas · doi:10.1097/mpa.0000000000001167 · Cited by 57

The role of endoscopic ultrasound in pancreatic cancer screening

Bhutani, M., Koduru, P., Joshi, V., Saxena, P., Suzuki, R., Irisawa, A., & Yamao, K. (2016) · Endoscopic Ultrasound · doi:10.4103/2303-9027.175876 · Cited by 55

Glutamine deprivation triggers NAGK-dependent hexosamine salvage

Campbell, S., Mesaros, C., Izzo, L., Affronti, H., Noji, M., Schaffer, B. E., Tsang, T., Sun, K., Trefely, S., Kruijning, S., et al. (2021) · eLife · doi:10.7554/elife.62644 · Cited by 58

Screening for Pancreatic Cancer

Lucas, A. L., & Kastrinos, F. (2019) · JAMA · doi:10.1001/jama.2019.9690 · Cited by 52

Interethnic differences in pancreatic cancer incidence and risk factors: The Multiethnic Cohort

Huang, B. Z., Stram, D. O., Le Marchand, L., Haiman, C. A., Wilkens, L. R., Pandol, S. J., Zhang, Z., Monroe, K. R., & Setiawan, V. W. (2019) · Cancer Medicine · doi:10.1002/cam4.2209 · Cited by 52

Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer

Lei, F., Xi, X., Batra, S. K., & Bronich, T. K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255786 · Cited by 51

Interactive 3D U-net for the segmentation of the pancreas in computed tomography scans

Boers, T. G. W., Hu, Y., Gibson, E., Barratt, D. C., Bonmati, E., Krdzalic, J., van der Heijden, F., Hermans, J. J., & Huisman, H. J. (2020) · Physics in Medicine & Biology · doi:10.1088/1361-6560/ab6f99 · Cited by 51

Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: A pilot study

Simpson, G., Spieler, B., Dogan, N., Portelance, L., Mellon, E. A., Kwon, D., Ford, J. C., & Yang, F. (2020) · Medical Physics · doi:10.1002/mp.14200 · Cited by 51

Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition

Yan, L., Tu, B., Yao, J., Gong, J., Carugo, A., Bristow, C. A., Wang, Q., Zhu, C., Dai, B., Kang, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3792 · Cited by 48

Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma

Koo, S.-Y., Park, E.-J., & Lee, C.-W. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0480-3 · Cited by 47

Biomarkers for early diagnosis of pancreatic cancer

Jenkinson, C., Earl, J., Ghaneh, P., Halloran, C., Carrato, A., Greenhalf, W., Neoptolemos, J., & Costello, E. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.965145 · Cited by 42

Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma

Anglin, J., Zavareh, R. B., Sander, P. N., Haldar, D., Mullarky, E., Cantley, L. C., Kimmelman, A. C., Lyssiotis, C. A., & Lairson, L. L. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.04.061 · Cited by 39